Glycemic Control and the Weight Benefit of a Daily 7 Mg Dose of Oral Semaglutide Versus an Alternate-Day 14 Mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Jul 11

PMID 37431351

Authors

Soumyabrata RoyChaudhuri

Anirban Majumder

Poulomi Mukherjee

Debmalya Sanyal

Soma Chakraborty

Susama Chuyan

Affiliations

Soon will be listed here.

Abstract

Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) class of antidiabetic medication. High costs and GI side effects are the major limitations of its widespread use. Some patients who were on a 14 mg dose of oral semaglutide self-prescribed an alternate-day schedule to mitigate GI side effects and to reduce the cost.

Methods: This retrospective observational cohort study evaluates the ambulatory glucose profile (AGP) data, extrapolated glycosylated hemoglobin (HbA1C), and BMI of 11 types of 2 diabetes mellitus (T2DM) while they were on an alternate-day 14 mg dose of oral semaglutide compared to their record while on a daily 7 mg dose. The AGP metrics (time-in-range (TIR), time-below-range (TBR), and time-above-range (TAR)) along with extrapolated HbA1C and BMI were analyzed. Statistical analysis was done using SPSS Statistics version 21.0.

Results: No statistically significant difference in the AGP metrics between the AGP profile of a daily 7 mg dose and the AGP profile of an alternate-day 14 mg dose of oral semaglutide was observed. Interestingly, a statistically significant progressive decline in BMI value was observed even on the alternate-day 14 mg dose when compared to the daily 7 mg dose.

Conclusion: In this small cohort of patients, the metrics of short-term glycemic control and the extrapolated HbA1C values were similar for the daily 7 mg dose versus the alternate-day 14 mg dose of oral semaglutide. BMI showed progressive reduction which was statistically significant even with the alternate-day 14 mg dose of oral semaglutide.

References

Federman A, Adams A, Ross-Degnan D, Soumerai S, Ayanian J . Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA. 2001; 286(14):1732-9. DOI: 10.1001/jama.286.14.1732. View

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701. PMC: 6245208. DOI: 10.2337/dci18-0033. View

Hernandez A, Green J, Janmohamed S, DAgostino Sr R, Granger C, Jones N . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X. View

Vigersky R, McMahon C . The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2018; 21(2):81-85. DOI: 10.1089/dia.2018.0310. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Tamblyn R, Laprise R, Hanley J, Abrahamowicz M, Scott S, Mayo N . Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001; 285(4):421-9. DOI: 10.1001/jama.285.4.421. View

Rector T . Exhaustion of drug benefits and disenrollment of medicare beneficiaries from managed care organizations. JAMA. 2000; 283(16):2163-7. DOI: 10.1001/jama.283.16.2163. View

Davies M, Pieber T, Hartoft-Nielsen M, Hansen O, Jabbour S, Rosenstock J . Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017; 318(15):1460-1470. PMC: 5817971. DOI: 10.1001/jama.2017.14752. View

10.

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

11.

RoyChaudhuri S, Majumder A, Sanyal D, Chakraborty S, Chuyan S . Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?. Cureus. 2023; 15(4):e37065. PMC: 10155755. DOI: 10.7759/cureus.37065. View

12.

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

13.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008; 360(2):129-39. DOI: 10.1056/NEJMoa0808431. View

14.

Dulay D, LaHaye S, Lahey K, Day A . Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol. 2009; 25(2):e28-31. PMC: 2691915. DOI: 10.1016/s0828-282x(09)70480-5. View

15.

Advani A . Positioning time in range in diabetes management. Diabetologia. 2019; 63(2):242-252. DOI: 10.1007/s00125-019-05027-0. View

16.

Piamsomboon C, Laothavorn P, Saguanwong S, Chatlaong B, Nasawadi C, Tanprasert P . Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J Med Assoc Thai. 2002; 85(3):297-300. View

17.

Soumerai S, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I . Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991; 325(15):1072-7. DOI: 10.1056/NEJM199110103251505. View

18.

Sikirica M, Martin A, Wood R, Leith A, Piercy J, Higgins V . Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017; 10:403-412. PMC: 5630073. DOI: 10.2147/DMSO.S141235. View

19.

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

20.

Granhall C, Donsmark M, Blicher T, Golor G, Sondergaard F, Thomsen M . Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clin Pharmacokinet. 2018; 58(6):781-791. DOI: 10.1007/s40262-018-0728-4. View